Eli Lilly reported Thursday that its experimental obesity drug, retatrutide, met all primary and key secondary endpoints in a late-stage clinical trial, delivering weight loss of up to 30% of body weight—a result that outstrips currently approved GLP-1 medications and approaches the effectiveness of bariatric surgery.
In the 80-week phase 3 study, patients receiving the highest once-weekly dose of retatrutide lost an average of 28.3% of their baseline weight, equivalent to 70.3 pounds. By comparison, the placebo group lost just 2.2%. The results are based on those who completed the trial, a common metric in obesity drug studies.
The lowest dose tested, with a single escalation step, still produced an average 19% weight loss—47.2 pounds. Among participants on the top dose, 65% achieved a body mass index below 30 after 80 weeks, moving out of the obesity range. Notably, 37.5% of those who started with class 3 obesity—BMI of 40 or higher—also fell below the obesity threshold.
An extended trial lasting 104 weeks focused on patients with a BMI of 35 or above. That group lost an average of 85 pounds, or 30% of their body weight. These figures rival the 30–35% weight loss typically seen two years after gastric bypass surgery.
Retatrutide is a triple hormone receptor agonist, targeting receptors for GIP, GLP-1, and glucagon. This mechanism appears to drive greater weight reduction than single- or dual-agonist drugs currently on the market, potentially positioning it as the most potent in the GLP-1 class.
However, the enhanced efficacy comes with a higher side-effect burden. Lilly reported that 11% of patients on the highest dose discontinued treatment due to adverse events—a rate above that seen with other anti-obesity drugs. Nausea affected 40% of that group, and vomiting occurred in 25%. Additionally, 12.5% experienced dysesthesia, a neurological condition causing unusual or painful skin sensations. Urinary tract infections were also reported in up to 9% of patients on the highest dose, compared with 5% on placebo—a finding not typically seen in other GLP-1 trials.
Full trial results are slated for presentation at the 86th annual American Diabetes Association Scientific Sessions. The data have not yet been peer-reviewed.
The strong weight-loss numbers come as policymakers and industry groups focus on lowering healthcare costs and expanding access to effective treatments. A Hill event is scheduled to address barriers in clinical trials, including for obesity drugs like retatrutide. Meanwhile, the broader debate over drug pricing and coverage continues, with Republicans eyeing the 2026 midterms and making cost-of-living issues central to their agenda.
If approved, retatrutide could reshape the obesity treatment landscape, but regulators and clinicians will weigh its significant side-effect profile against its unmatched efficacy.
